Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Glioblastoma 4Gliosarcoma 2Brain Neoplasms 2Sarcoma, Kaposi 1Sarcoma 1Recurrence 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Congenital Abnormalities 1Astrocytoma 1AIDS-related Kaposi sarcoma 1

Interventions

tanespimycin 1entinostat 1eltrombopag 1alvocidib 1Sorafenib 1Mitoxantrone 1Idarubicin 1Etoposide 1Cytarabine 1Cilengitide 1Bortezomib 1Bevacizumab 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Eosinophilic, Acute × Cilengitide × Clear all
NCT00089388 2013-01-24

Cilengitide in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Terminated
70 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡